Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant

ROS1 fusion is a common genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases with ROS1 translocation. We report the response to crizotinib of a lung adenocarcinoma patient harboring a novel SLC34A2...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zheng, Song, Zhangjun, Wang, Xuwei, Sun, Haifeng, Yang, Xiaomin, Yuan, Yong, Yu, Pan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571840/
https://www.ncbi.nlm.nih.gov/pubmed/28860822
http://dx.doi.org/10.2147/OTT.S136297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571840/
https://www.ncbi.nlm.nih.gov/pubmed/28860822
http://dx.doi.org/10.2147/OTT.S136297

Ejemplares similares